Robert A. Wolff
Impact in
- Oncology top 0.01%
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
- Cancer Research top 0.1%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 306
- Pancreatic and Hepatic Oncology Research 201
- Colorectal Cancer Treatments and Studies 74
- Cancer Immunotherapy and Biomarkers 22
- Cancer Research 110
- Cancer Genomics and Diagnostics 84
- Co-authors
- James L. Abbruzzese (109 shared papers)Christopher H. Crane (95 shared papers)Douglas B. Evans (67 shared papers)Peter W. T. Pisters (61 shared papers)Jeffrey E. Lee (67 shared papers)Gauri R. Varadhachary (111 shared papers)Donghui Li (12 shared papers)Jean‐Nicolas Vauthey (43 shared papers)
- Journals
- Journal of Clinical Oncology (150 papers)Cancer (24 papers)International Journal of Radiation Oncology*Biology*Physics (22 papers)Annals of Surgical Oncology (20 papers)Oncotarget (11 papers)
- Partner nations
- United StatesEgyptBrazil
In The Last Decade
Robert A. Wolff
449 papers receiving 28.6k citations
Robert A. Wolff's Hit Papers
Peers
Comparison fields: 5 of 155
- Oncology 18.5k
- Cancer Research 4.2k
- Hepatology 1.3k
- Gastroenterology 859
- Pulmonary and Respiratory Medicine 4.9k
Countries citing papers authored by Robert A. Wolff
This map shows the geographic impact of Robert A. Wolff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert A. Wolff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert A. Wolff more than expected).
Fields of papers citing papers by Robert A. Wolff
This network shows the impact of papers produced by Robert A. Wolff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert A. Wolff. The network helps show where Robert A. Wolff may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert A. Wolff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 464 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group Hit paper breakdown → | 2007 | 2920 |
| 2 | Pancreatic cancer Hit paper breakdown → | 2004 | 1499 |
| 3 | Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer Hit paper breakdown → | 2008 | 1071 |
| 4 | Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy Hit paper breakdown → | 2006 | 640 |
| 5 | Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease Hit paper breakdown → | 2008 | 597 |
| 6 | Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head Hit paper breakdown → | 2008 | 534 |
| 7 | Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study Hit paper breakdown → | 2008 | 494 |
| 8 | A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group Hit paper breakdown → | 2020 | 471 |
| 9 | 2007 | 444 | |
| 10 | Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases Hit paper breakdown → | 2008 | 431 |
| 11 | 2004 | 428 | |
| 12 | 2004 | 420 | |
| 13 | 2012 | 396 | |
| 14 | 2004 | 391 | |
| 15 | 2009 | 383 | |
| 16 | 2009 | 378 | |
| 17 | 1999 | 372 | |
| 18 | Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications Hit paper breakdown → | 2014 | 349 |
| 19 | 2008 | 347 | |
| 20 | Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers Hit paper breakdown → | 2019 | 334 |
About Robert A. Wolff
Robert A. Wolff is a scholar working on Oncology, Cancer Research, Surgery, Pulmonary and Respiratory Medicine and Epidemiology, having authored 464 papers that have together received 29.1k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (201 papers), Cancer Genomics and Diagnostics (84 papers), Colorectal Cancer Treatments and Studies (74 papers), Neuroendocrine Tumor Research Advances (34 papers), Colorectal and Anal Carcinomas (30 papers), Renal cell carcinoma treatment (30 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (28 papers) and Cancer Immunotherapy and Biomarkers (22 papers). The work is most often cited by research in Oncology (18.5k citations), Cancer Research (4.2k citations), Hepatology (1.3k citations), Gastroenterology (859 citations) and Pulmonary and Respiratory Medicine (4.9k citations). Robert A. Wolff has collaborated with scholars based in United States, Egypt and Brazil. Frequent co-authors include James L. Abbruzzese, Christopher H. Crane, Douglas B. Evans, Peter W. T. Pisters, Jeffrey E. Lee, Gauri R. Varadhachary, Donghui Li, Jean‐Nicolas Vauthey, Huamin Wang and Keping Xie. Their work appears in journals such as Journal of Clinical Oncology, Cancer, International Journal of Radiation Oncology*Biology*Physics, Annals of Surgical Oncology and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.